清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Clinical Evaluation of NESOSPRAY HE-C, a Nasal Spray, for Rhinopharyngitis and Rhinosinusitis: A Randomized, Double-Blind, Placebo-Controlled Trial

安慰剂 双盲 医学 慢性鼻-鼻窦炎 鼻喷雾剂 随机对照试验 麻醉 内科学 鼻腔给药 药理学 病理 替代医学
作者
Fatima-Zahra El Barche,Manon D’almeida,Séverine Dameron,Remi Shrivastava
出处
期刊:Medicina-lithuania [Multidisciplinary Digital Publishing Institute]
卷期号:61 (6): 1071-1071 被引量:2
标识
DOI:10.3390/medicina61061071
摘要

Background and Objectives: The common cold (acute rhinopharyngitis) and acute rhinosinusitis are highly prevalent conditions that significantly impact quality of life, often leading to nasal congestion, inflammation, and discomfort. Given the growing demand for non-pharmacological treatment options, particularly for vulnerable populations such as children and pregnant women, alternative therapies are increasingly being explored. NESOSPRAY HE-C, a nasal spray formulated with a glycerol-based filmogenic solution, acts by forming a protective osmotic film on the nasal mucosa. This mechanism facilitates mechanical cleansing, enhances decongestion, and reduces inflammation while preserving mucosal integrity. Its purely topical and mechanical mode of action provides a non-systemic alternative for symptom management. Materials and Methods: This randomized, double-blind, parallel-group clinical trial evaluated the efficacy and safety of NESOSPRAY HE-C (n = 29) compared to a placebo nasal spray (n = 26) in patients aged ≥ 3 years diagnosed with the common cold or acute rhinosinusitis. Participants had a baseline Rhinosinusitis Symptom Severity Score (RSSS) of ≥25/50. Treatment consisted of administering 2–3 sprays per nostril, four times daily, every 4 to 6 h, for up to 8 days or until symptom resolution. The primary outcomes included changes in total RSSS, Wisconsin Upper Respiratory Symptom Survey (WURSS) score, and individual symptom scores (rhinorrhea, nasal congestion, cough, poor sleep, facial pain, and fever). Safety assessments included adverse event monitoring and treatment tolerability, with subgroup analyses performed for children and pregnant women. Results: Baseline demographics were comparable between the treatment groups. NESOSPRAY HE-C demonstrated a significantly greater reduction in total RSSS from Day 3 onward (p = 0.0008), with sustained superiority through Day 8 (p < 0.0001). Significant improvements in rhinorrhea and nasal congestion were observed within 2 h of administration (p = 0.0089), while reductions in cough (p = 0.0052), poor sleep (p = 0.0005), and facial pain (p = 0.0111) emerged by Day 3. Fever reduction was most pronounced on Days 6 (p = 0.0001) and 8 (p = 0.0312), indicating a delayed but significant effect. In terms of the WURSS score, NESOSPRAY HE-C showed a significant improvement from Day 1, with a greater reduction in symptom severity compared to placebo. This trend of greater improvement continued through Day 8. The treatment was well tolerated, with no reports of serious adverse events or allergic reactions. Efficacy was consistent across all subgroups, including children, pregnant women, and adults. Conclusions: NESOSPRAY HE-C provides rapid and sustained symptom relief for the common cold and acute rhinosinusitis, serving as a safe and effective non-pharmacological alternative to conventional treatments. By leveraging its osmotic action and barrier-forming properties, it facilitates mechanical cleansing, enhances decongestion, and reduces inflammation while preserving mucosal integrity. Additionally, by forming a protective film on the nasal mucosa, it protects against future irritations, further supporting its role as a valuable therapeutic option, particularly for individuals seeking non-systemic symptom management.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
隐形的灵薇完成签到,获得积分10
20秒前
mickaqi完成签到 ,获得积分10
25秒前
柔弱的妙旋完成签到,获得积分10
34秒前
limengyao完成签到,获得积分10
58秒前
lzm完成签到 ,获得积分10
1分钟前
水water完成签到 ,获得积分10
1分钟前
虎子完成签到 ,获得积分10
1分钟前
激情的汲完成签到,获得积分10
1分钟前
小珂完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
Gone完成签到,获得积分10
1分钟前
SciGPT的应助被兰兰不懒采纳,获得10
2分钟前
2分钟前
yc关闭了yc的文献求助
2分钟前
VuuVuu完成签到,获得积分10
2分钟前
顺利的雅旋完成签到,获得积分10
2分钟前
2分钟前
兰兰不懒发布了新的文献求助10
2分钟前
淡淡依霜完成签到 ,获得积分10
2分钟前
廖道罡完成签到,获得积分10
2分钟前
温婉的乐荷完成签到,获得积分10
2分钟前
VuuVuu发布了新的文献求助10
3分钟前
852的应助被LY采纳,获得10
3分钟前
简单完成签到 ,获得积分10
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
isssstwice发布了新的文献求助30
3分钟前
isssstwice完成签到,获得积分10
4分钟前
doudou完成签到,获得积分10
4分钟前
落后的山槐完成签到,获得积分10
4分钟前
5分钟前
LY发布了新的文献求助10
5分钟前
活力尔柳完成签到 ,获得积分10
5分钟前
lilylwy完成签到 ,获得积分0
5分钟前
朝朝的应助被萧雨墨采纳,获得10
5分钟前
单纯的天抒完成签到,获得积分10
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190226
求助须知:如何正确求助?哪些是违规求助? 9577355
关于积分的说明 21852358
捐赠科研通 7788741
什么是DOI,文献DOI怎么找? 3436310
关于科研通互助平台的介绍 2560106
邀请新用户注册赠送积分活动 2482902